Genenta Science CEO owns 10% stake through market purchases
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/24/2026
- S&P 500 ends marginally lower as investors focus on US-Iran war
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oil gains on little sign of progress in US-Iran talks
- S&P 500 history shows strong gains across Fed hiking cycles: BCA
- JPMorgan upgrades CoreWeave on stronger compute pricing
- Plug Power COO resigns to join another company
- Bloom Energy falls as Oracle invokes force majeure on AI project
- Oracle triggers force majeure on massive 'Project Jupiter' data center
- Oracle Sends Force Majeure Notice Over New Mexico Data Center - Bloomberg
- Akamai signs $11.6B deal with Anthropic, up to $20B potential
Genenta Science Provides Update on CEO Ownership
December 19, 2025 2:30 AM ESTMILAN and NEW YORK, Dec. 19, 2025 (GLOBE NEWSWIRE) -- Genenta Science (Nasdaq: GNTA), a clinical-stage gene-therapy company developing hematopoietic stem-cell-based immunotherapies for solid tumors, provides an update regarding the ownership position of its Chief Executive Officer and Co-Founder, Pierluigi Paracchi.
Over time, Mr. Paracchi has acquired 30,000 American Depositary Shares (ADSs) of the Company in total through open-market purchases. As reported in the Companys filings with the U.S. Securities and Exchange Commission (SEC), Mr. Paracchis transactions in the Companys securities have... More
